Communiqués Toleranzia AB

Actions

Temps Différé Nasdaq Stockholm Autres places de cotation 09:41:36 10/06/2024			Varia. 5j.	Varia. 1 janv.
0,7 ^SEK	0,00 %		+7,36 %	+63,55 %

31/05	Toleranzia AB (publ) mène avec succès une étude d'innocuité du TOL2 dans des échantillons de sang de patients atteints de myasthénie grave	CI
20/05	Toleranzia AB publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis	31/05	AQ
Toleranzia : Annual General Meeting 2024 06 19 – Postal voting form	28/05	PU
Toleranzia : Annual General Meeting 2024 06 19 – Proxy form	28/05	PU
Toleranzia : Annual General Meeting 2024 06 19 – Annual Report 2023	28/05	PU
Toleranzia : Annual General Meeting 2024 06 19 – Auditor’s Report 2023	28/05	PU
Notice of Annual General Meeting in Toleranzia AB (publ)	20/05	AQ
Toleranzia AB: Interim report first quarter 2024	20/05	AQ
Toleranzia AB: Annual report for the financial year 2023	30/04	AQ
Toleranzia AB receives loan commitment of SEK 20 million	24/04	AQ
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	18/03	AQ
Toleranzia AB – Year-End Report 2023	23/02	AQ
Toleranzia successfully completes GLP toxicology study of TOL2	15/01	AQ
Toleranzia AB starts production of finished drug product for clinical studies	21/12	AQ
Toleranzia AB presents Nomination Committee	15/12	AQ
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	06/12	AQ
Toleranzia AB: Interim report third quarter 2023	27/10/23	AQ
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	16/10/23	AQ
Toleranzia starts toxicology study of its lead drug candidate TOL2	26/09/23	AQ
Toleranzia announces outcome in rights issue	15/09/23	AQ
Toleranzia publishes prospectus in connection with rights issue of units	28/08/23	AQ

Aucun résultat pour cette recherche